Abstract:Cytotoxic accumulation of loosely bound mitochondrial Fe 2+ is a hallmark of Friedreich's Ataxia (FA), a rare and fatal neuromuscular disorder with limited therapeutic options. There are no clinically approved medications targeting excess Fe 2+ associated with FA or the neurological disorders Parkinson's disease and Multiple System Atrophy. Traditional iron-chelating drugs clinically approved for systemic iron overload that target ferritin-stored Fe 3+ for urinary excretion demonstrated limited efficacy in FA and exacerbated ataxia. Poor treatment outcomes reflect inadequate binding to excess toxic Fe 2+ or exceptionally high affinities (i.e. ≤10 -31 ) for non-pathologic Fe 3+ that disrupts intrinsic iron homeostasis. To understand previous treatment failures and identify beneficial factors for Fe 2+ -targeted therapeutics, we compared traditional Fe 3+ chelators deferiprone (DFP) and deferasirox (DFX) with additional iron-binding compounds including ATH434, DMOG, and IOX3. ATH434 and DFX had moderate Fe 2+ binding affinities ( K d 's of 1-4 μM), similar to endogenous iron chaperones, while the remaining had weaker divalent metal interactions. These compounds had low/moderate affinities for Fe 3+ (0.46-9.59 μM) relative to DFX and DFP. While all compounds coordinated iron using molecular oxygen and/or nitrogen ligands, thermodynamic analyses suggest ATH434 completes Fe 2+ coordination using H 2 O. ATH434 significantly stabilized bound Fe 2+ from ligand-induced autooxidation, reducing reactive oxygen species (ROS) production, whereas DFP and DFX promoted production. The comparable affinity of ATH434 for Fe 2+ and Fe 3+ position it to sequester excess Fe 2+ and facilitate drug-to-protein iron metal exchange, mimicking natural endogenous iron binding proteins, at a reduced risk of autooxidation-induced ROS generation or perturbation of cellular iron stores. Graphical Open in new tabDownload slide

Deferasirox-TAT(47–57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine

A Water-Soluble Chitosan Derivative for the Release of Bioactive Deferoxamine

A Small Molecular “albumin Hitchhiking” Deferoxamine Conjugate Improved Iron Clearance Efficacy

New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis

ATH434, a promising iron-targeting compound for treating iron regulation disorders

From Small Deferiprone to Macromolecular Micelles: Self-assembly Enhances Iron Chelation.

[Deferasirox--a New Oral Iron Chelator--review].

Deferasirox (ExJade): An FDA-Approved AIEgen Platform with Unique Photophysical Properties

Polymeric Nanoparticles Enhance the Ability of Deferoxamine to Deplete Hepatic and Systemic Iron

Deferasirox's Anti-Chemoresistance and Anti-Metastatic Effect on Non-Small Cell Lung Carcinoma

Cell Permeable Imidazole-Desferrioxamine Conjugates: Synthesis and In Vitro Evaluation

Potential anticancer effect of free and nanoformulated Deferasirox for breast cancer treatment: in-vitro and in-vivo evaluation

Iron Chelator Deferasirox Rescued Mice from Fas‐induced Fulminant Hepatitis

In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics

PEGylation of Deferoxamine for Improving the Stability, Cytotoxicity, and Iron-Overload in an Experimental Stroke Model in Rats

Mitochondrially targeted deferasirox kills cancer cells simultaneous iron deprivation and ferroptosis induction

A DFX-based iron nanochelator for cancer therapy

Synthesis of Deferasirox,an Iron Chelator

The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells

New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study

Deferasirox exerts anti-epileptic effects by improving brain iron homeostasis via regulation of ITPRIP